Logo image of PSTV

PLUS THERAPEUTICS INC (PSTV) Stock Fundamental Analysis

NASDAQ:PSTV - Nasdaq - US72941H5090 - Common Stock - Currency: USD

0.299  -0.01 (-4.47%)

After market: 0.303 +0 (+1.34%)

Fundamental Rating

1

Taking everything into account, PSTV scores 1 out of 10 in our fundamental rating. PSTV was compared to 560 industry peers in the Biotechnology industry. PSTV may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, PSTV is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year PSTV has reported negative net income.
PSTV had a negative operating cash flow in the past year.
In the past 5 years PSTV always reported negative net income.
In the past 5 years PSTV always reported negative operating cash flow.
PSTV Yearly Net Income VS EBIT VS OCF VS FCFPSTV Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M -25M

1.2 Ratios

PSTV's Return On Assets of -195.66% is on the low side compared to the rest of the industry. PSTV is outperformed by 89.32% of its industry peers.
Industry RankSector Rank
ROA -195.66%
ROE N/A
ROIC N/A
ROA(3y)-132.52%
ROA(5y)-105.31%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
PSTV Yearly ROA, ROE, ROICPSTV Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for PSTV so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PSTV Yearly Profit, Operating, Gross MarginsPSTV Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K

More info and screens

0

2. Health

2.1 Basic Checks

PSTV does not have a ROIC to compare to the WACC, probably because it is not profitable.
PSTV has more shares outstanding than it did 1 year ago.
PSTV has more shares outstanding than it did 5 years ago.
PSTV has a worse debt/assets ratio than last year.
PSTV Yearly Shares OutstandingPSTV Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M 5M
PSTV Yearly Total Debt VS Total AssetsPSTV Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

Based on the Altman-Z score of -112.26, we must say that PSTV is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -112.26, PSTV is doing worse than 97.51% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -112.26
ROIC/WACCN/A
WACC7.52%
PSTV Yearly LT Debt VS Equity VS FCFPSTV Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M -20M

2.3 Liquidity

PSTV has a Current Ratio of 0.34. This is a bad value and indicates that PSTV is not financially healthy enough and could expect problems in meeting its short term obligations.
PSTV's Current ratio of 0.34 is on the low side compared to the rest of the industry. PSTV is outperformed by 94.84% of its industry peers.
PSTV has a Quick Ratio of 0.34. This is a bad value and indicates that PSTV is not financially healthy enough and could expect problems in meeting its short term obligations.
PSTV's Quick ratio of 0.34 is on the low side compared to the rest of the industry. PSTV is outperformed by 94.31% of its industry peers.
Industry RankSector Rank
Current Ratio 0.34
Quick Ratio 0.34
PSTV Yearly Current Assets VS Current LiabilitesPSTV Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 52.10% over the past year.
Looking at the last year, PSTV shows a quite strong growth in Revenue. The Revenue has grown by 18.54% in the last year.
Measured over the past years, PSTV shows a decrease in Revenue. The Revenue has been decreasing by -3.61% on average per year.
EPS 1Y (TTM)52.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%41.67%
Revenue 1Y (TTM)18.54%
Revenue growth 3YN/A
Revenue growth 5Y-3.61%
Sales Q2Q%7.54%

3.2 Future

The Earnings Per Share is expected to grow by 25.24% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 102.09% on average over the next years. This is a very strong growth
EPS Next Y59.93%
EPS Next 2Y28.08%
EPS Next 3Y23.44%
EPS Next 5Y25.24%
Revenue Next Year19.43%
Revenue Next 2Y14.01%
Revenue Next 3Y87.71%
Revenue Next 5Y102.1%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
PSTV Yearly Revenue VS EstimatesPSTV Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M
PSTV Yearly EPS VS EstimatesPSTV Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -500K -1M -1.5M -2M -2.5M

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

PSTV reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PSTV. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PSTV Price Earnings VS Forward Price EarningsPSTV Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PSTV Per share dataPSTV EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5 -2

4.3 Compensation for Growth

A more expensive valuation may be justified as PSTV's earnings are expected to grow with 23.44% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.08%
EPS Next 3Y23.44%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for PSTV!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PLUS THERAPEUTICS INC

NASDAQ:PSTV (5/23/2025, 8:48:29 PM)

After market: 0.303 +0 (+1.34%)

0.299

-0.01 (-4.47%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-13 2025-05-13/amc
Earnings (Next)08-12 2025-08-12/amc
Inst Owners8.46%
Inst Owner Change-42.62%
Ins Owners2.55%
Ins Owner Change0%
Market Cap5.08M
Analysts82
Price Target9.82 (3184.28%)
Short Float %13.51%
Short Ratio0.1
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)19.39%
Min EPS beat(2)3.28%
Max EPS beat(2)35.51%
EPS beat(4)3
Avg EPS beat(4)16.94%
Min EPS beat(4)-3.59%
Max EPS beat(4)35.51%
EPS beat(8)6
Avg EPS beat(8)20.63%
EPS beat(12)7
Avg EPS beat(12)6.77%
EPS beat(16)9
Avg EPS beat(16)4.61%
Revenue beat(2)1
Avg Revenue beat(2)15.8%
Min Revenue beat(2)-5.88%
Max Revenue beat(2)37.49%
Revenue beat(4)1
Avg Revenue beat(4)0.97%
Min Revenue beat(4)-25.16%
Max Revenue beat(4)37.49%
Revenue beat(8)3
Avg Revenue beat(8)14.57%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-6.85%
PT rev (3m)-6.1%
EPS NQ rev (1m)25.42%
EPS NQ rev (3m)56.86%
EPS NY rev (1m)15.8%
EPS NY rev (3m)42.79%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-14.42%
Revenue NY rev (1m)0%
Revenue NY rev (3m)34.78%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.87
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.17
EYN/A
EPS(NY)-0.87
Fwd EYN/A
FCF(TTM)-0.66
FCFYN/A
OCF(TTM)-0.62
OCFYN/A
SpS0.34
BVpS-0.53
TBVpS-0.58
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -195.66%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-132.52%
ROA(5y)-105.31%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.88
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 95.57%
Cap/Sales 11.86%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.34
Quick Ratio 0.34
Altman-Z -112.26
F-Score4
WACC7.52%
ROIC/WACCN/A
Cap/Depr(3y)67.77%
Cap/Depr(5y)74.15%
Cap/Sales(3y)82.31%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)52.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%41.67%
EPS Next Y59.93%
EPS Next 2Y28.08%
EPS Next 3Y23.44%
EPS Next 5Y25.24%
Revenue 1Y (TTM)18.54%
Revenue growth 3YN/A
Revenue growth 5Y-3.61%
Sales Q2Q%7.54%
Revenue Next Year19.43%
Revenue Next 2Y14.01%
Revenue Next 3Y87.71%
Revenue Next 5Y102.1%
EBIT growth 1Y-10.32%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year8.2%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y13.57%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y17.87%
OCF growth 3YN/A
OCF growth 5YN/A